about
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.Sister Mary Joseph's nodule in advanced ovarian cancer.Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.Impact of providing booklets about chemotherapy to newly presenting patients with cancer: a randomized controlled trial.Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy.bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer.Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
P50
Q31051431-DAF368D4-D394-466D-8564-6A3C4CCF4350Q33337182-5B423FBC-840D-4DAA-909E-8E2FCEC019F1Q33339670-79952BE5-1A4F-48C8-9A5A-8E80775A532FQ33339836-5C7991A8-ABF7-4D68-988B-F63D1940FF75Q33340278-24BCB429-382B-4839-84EB-5C12D2416805Q33346271-4AC29552-FF62-42AB-83C2-663958A8B5FEQ33371394-C6D97E44-98C7-40C2-8240-AEA832CE10FBQ33376233-02338D5F-BEC4-457C-BFE8-B1D7BB3C41A9Q33919277-F9338F4B-B7BA-4850-AA80-178ADE6B2C21Q36551631-E037E58F-BFDA-4A5D-A017-100986DE0A17Q36864879-CEE8A6CB-8EB8-4118-91F9-9F7CB4A9B26AQ37404101-D23B1E4F-FF2D-4F64-88E0-3E280E76A625Q40517493-83B1C231-0B10-447F-ADA4-B8F0DC964EF4Q43146147-AD5ED621-5E83-4D9C-8A43-330A44FA18EFQ43576742-B214A216-A067-4D58-B3E9-CDD84B4707FFQ44143000-10A66830-8C18-4EFF-93C4-75118A48BAA4Q44207606-BEBE20DD-47D7-4F6B-B5B7-F93F517C900CQ44362051-CCCE3CF5-5342-47EA-B76F-019B250B7628Q44508381-CCF8EA64-1201-4366-BA0B-328398D871EFQ44672047-E04921AF-E19F-411F-8DBA-91EAB5C99C1FQ44736596-D4B898D0-3BC0-47D4-82FB-422A527175A0Q44752761-B8D708B8-BD59-4920-85B5-B90E81600B79Q45059044-1A20E723-EAAC-4231-B8BD-11DD2935A298Q46474794-19CE42C5-0F71-495F-82DD-BE65EC43274CQ46592751-87AB1860-6053-475E-9C1E-121330626529Q46691182-79407DAD-BFCD-4ECF-AEC6-02AD6A1383D7Q46704256-3EFD21BD-CA84-4602-8055-09FAFEC04BC2Q46784435-ABC6D440-289E-4135-9555-2ABE1C25CCFEQ46949245-278D470F-7998-4113-935A-609182997FB1Q50887433-01242E18-25A8-4422-9BEA-5D344EC4E854Q50922149-EE9AC1AA-FD24-4DB6-9C21-21C9CDDB2A61Q50950917-A3AD2EB9-5C88-4434-A9C8-BE0F2246F5E3Q51887350-41F339E4-5A62-4730-922A-3EE1102E8CB5Q53984654-2B225EC4-27F4-4DB6-81E1-956454F1F7FDQ54154993-DEA93C0B-9277-46D4-A152-38A573A5034C
P50
name
H P Kalofonos
@ast
H P Kalofonos
@en
H P Kalofonos
@nl
type
label
H P Kalofonos
@ast
H P Kalofonos
@en
H P Kalofonos
@nl
prefLabel
H P Kalofonos
@ast
H P Kalofonos
@en
H P Kalofonos
@nl